INVESTIGATIONAL NEW DRUG APPLICATION
\ɪnvˌɛstɪɡˈe͡ɪʃənə͡l njˈuː dɹˈʌɡ ˌaplɪkˈe͡ɪʃən], \ɪnvˌɛstɪɡˈeɪʃənəl njˈuː dɹˈʌɡ ˌaplɪkˈeɪʃən], \ɪ_n_v_ˌɛ_s_t_ɪ_ɡ_ˈeɪ_ʃ_ə_n_əl n_j_ˈuː d_ɹ_ˈʌ_ɡ ˌa_p_l_ɪ_k_ˈeɪ_ʃ_ə_n]\
Sort: Oldest first
-
An application that must be submitted to a regulatory agency (the FDA in the United States) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (From the "New Medicines in Development" Series produced by the Pharmaceutical Manufacturers Association and published irregularly.)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.